In ₹ Crore except Per Share Latest Annual	JKLAKSHMI FY26	JKCEMENT FY26	ULTRACEMCO FY26	AMBUJACEM FY26	Peer Average
Valuation — at last close
P/E	◆ 14.39×	37.99×	39.28×	18.77×	32.02× -55%
P/B	1.53×	5.36×	4.19×	◆ 1.50×	3.68× -59%
EV/EBITDA	◆ 7.11×	18.25×	20.16×	15.36×	17.92× -60%
Market Cap	₹5,930 Cr	₹37,708 Cr	₹3.21L Cr	₹88,861 Cr	₹1.49L Cr -96%
Growth
Revenue CAGR 3Y	1.58%	◆ 12.18%	11.86%	1.45%	8.50% -81%
Revenue CAGR 5Y	7.42%	◆ 15.74%	14.63%	7.02%	12.46% -40%
Net Income CAGR 3Y	3.78%	◆ 33.09%	17.30%	23.07%	24.49% -85%
Revenue YoY (latest Q)	9.41%	◆ 23.66%	18.81%	0.25%	14.24% -34%
Net Income YoY (latest Q)	-27.90%	6.31%	◆ 21.28%	-89.75%	-20.72% -35%
Profitability
EBITDA Margin	14.95%	17.30%	◆ 19.23%	16.08%	17.54% -15%
Net Income Margin	6.10%	7.20%	9.25%	◆ 13.87%	10.11% -40%
Return on Common Equity	11.20%	◆ 15.12%	11.08%	8.38%	11.53% -3%
Return on Capital Employed	10.41%	◆ 12.85%	11.85%	4.13%	9.61% +8%
Return on Assets	4.85%	5.62%	5.95%	◆ 6.61%	6.06% -20%
Credit & Quality
Total Debt/Equity	0.64×	0.86×	0.28×	◆ 0.00×	0.38× +68%
Interest Coverage	3.26×	4.06×	6.61×	◆ 13.28×	7.98× -59%
Scale — latest FY
Revenue / Total Income	₹6,763 Cr	₹13,722 Cr	₹88,512 Cr	₹40,656 Cr	₹47,630 Cr -86%
Net Income	₹413 Cr	₹988 Cr	₹8,188 Cr	₹5,637 Cr	₹4,938 Cr -92%
Total Assets	₹8,548 Cr	₹18,500 Cr	₹1.41L Cr	₹89,607 Cr	₹83,161 Cr -90%
EPS	₹33.19	₹128.44	₹277.62	₹19.15	₹141.74 -77%
Book Value per Share	₹312.9	₹910.74	₹2,600.23	₹240.1	₹1,250.36 -75%

◆ best value in the comp set per metric · Δ = subject vs average of the other companies.

« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave

Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.